Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Open Access
- 18 July 2020
- Vol. 12 (7), 1955
- https://doi.org/10.3390/cancers12071955
Abstract
Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30 years and is likely to further increase, making PDAC a leading cause of cancer-related death in the coming years. PDAC is typically diagnosed at an advanced stage, and modified FOLFIRINOX or nab-paclitaxel and gemcitabine are the mainstay of systemic therapy. For elderly patients with good performance status, low-dose treatment can preserve quality of life without compromising cancer control or survival. Maintenance therapy should be considered in PDAC patients achieving disease control with systemic therapy. In particular, olaparib has demonstrated a progression-free survival benefit of 3.6 months in a subgroup of PDAC patients with germline BRCA1/2 mutations (ca. 10% of all PDAC). Pancreatic enzyme replacement therapy is often omitted in the treatment of patients with PDAC, with possibly deleterious consequences. Small intestinal bacterial overgrowth is highly prevalent in patients with PDAC and should be considered in the diagnostic algorithm of PDAC patients with bloating and diarrhea. Rivaroxaban has been associated with a reduced risk of thrombosis without an increase in major bleeding events, and its use should be considered in every patient with advanced PDAC undergoing systemic therapy.This publication has 85 references indexed in Scilit:
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patientsJournal of Thrombosis and Haemostasis, 2012
- The Daily Practice of Pancreatic Enzyme Replacement Therapy After Pancreatic Surgery: a Northern European SurveyJournal of Gastrointestinal Surgery, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancerThrombosis and Haemostasis, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLoS Medicine, 2010
- Tolerance and Efficacy of Gemcitabine and Gemcitabine-Based Regimens in Elderly Patients With Advanced Pancreatic CancerPancreas, 2008
- Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic CancerClinical Cancer Research, 2007
- Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)Annals of Oncology, 2005
- Tissue factor expression correlates with histological grade in human pancreatic cancerBritish Journal of Surgery, 1995